Insight Molecular Diagnostics to announce Q3 results on November 10, 2025, and participate in the Stephens NASH25 Conference.
Quiver AI Summary
Insight Molecular Diagnostics Inc. (iMDx) announced that it will release its third quarter 2025 financial results on November 10, 2025, after market hours. A live Zoom webinar to discuss the results will be held at 2:00 PM PT / 5:00 PM ET on the same day, with registration required. An archived replay will be available on the company's investor relations website after the event. Additionally, CEO Josh Riggs will participate in the Stephens NASH25 Conference in Nashville, TN, on November 19, 2025. iMDx, formerly Oncocyte Corp., focuses on precision diagnostics and aims to improve patient outcomes through innovative molecular diagnostic testing. The company relocated its headquarters to Nashville in June 2025 and changed its NASDAQ symbol at that time.
Potential Positives
- Insight Molecular Diagnostics Inc. will report its third quarter 2025 financial results on November 10, providing investors with timely updates on the company's performance.
- The live Zoom webinar following the financial results will allow for direct engagement between the company's management and investors, fostering transparency and open communication.
- Participation in the Stephens NASH25 Conference provides an opportunity for iMDx to showcase its advancements in precision diagnostics and enhance visibility among the investment community.
- The relocation of the company's headquarters to Nashville and its new NASDAQ symbol indicate a strategic repositioning that may enhance its market presence and investor appeal.
Potential Negatives
- Company has not yet reported third quarter financial results, which may create uncertainty among investors about its financial health.
- Transition from Oncocyte Corp. to Insight Molecular Diagnostics Inc. could lead to brand recognition challenges and confusion among stakeholders.
- Moving the headquarters may indicate operational instability or restructuring within the company, potentially raising concerns about its strategic direction.
FAQ
When will iMDx report its Q3 2025 financial results?
iMDx will report its Q3 2025 financial results on November 10, 2025, after the market closes.
How can I attend the iMDx Q3 2025 earnings webinar?
You can attend the iMDx Q3 2025 earnings webinar by registering at the link provided in the press release.
What is the date of the Stephens NASH25 Conference?
The Stephens NASH25 Conference will take place from November 18-20, 2025, with iMDx participating on November 19.
Who will represent iMDx at the Stephens NASH25 Conference?
Chief Executive Officer Josh Riggs will attend the Stephens NASH25 Conference representing iMDx.
Where can I find the archived replay of the earnings webinar?
The archived replay of the earnings webinar will be available on iMDx’s investor relations website after the call concludes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMDX Hedge Fund Activity
We have seen 1 institutional investors add shares of $IMDX stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEFENDER CAPITAL, LLC. added 32,928 shares (+inf%) to their portfolio in Q2 2025, for an estimated $99,442
- SG AMERICAS SECURITIES, LLC removed 16,585 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $50,086
- ORG PARTNERS LLC removed 650 shares (-59.1%) from their portfolio in Q3 2025, for an estimated $2,158
- WILMINGTON SAVINGS FUND SOCIETY, FSB removed 250 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $755
- PISCATAQUA SAVINGS BANK added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IMDX Analyst Ratings
Wall Street analysts have issued reports on $IMDX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 08/18/2025
To track analyst ratings and price targets for $IMDX, check out Quiver Quantitative's $IMDX forecast page.
Full Release
NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 10, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q3 2025 Earnings Webinar .
An archived replay will be available after the call concludes on iMDX’s investor relations website at https://investors.imdxinc.com/ .
Stephens NASH25 Conference
Separately, on November 19
th
, Chief Executive Officer Josh Riggs will attend the Stephens NASH25 Conference, taking place from November 18-20, 2025.
Investors wishing to book one-on-one meetings with management are encouraged to reach out to their Stephens sales representative.
Event:
Stephens NASH25 Conference
Dates:
November 19, 2025
Location:
Nashville, TN
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering precision diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. iMDx utilizes a well-established proprietary approach to quantify dd-cfDNA, which is a widely used molecular biomarker of transplant rejection.
iMDx™, GraftAssure™, GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company’s new NASDAQ symbol became effective June 18. Investors may visit https://investors.imdxinc.com/ for more information.
Investor Contact:
Doug Farrell
LifeSci Advisors LLC
[email protected]
